Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1404213.RAppPbBBST-2J_C8aaueTXrzoSp9jR0y24e9krOW2p1MY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1404213.RAppPbBBST-2J_C8aaueTXrzoSp9jR0y24e9krOW2p1MY130_assertion type Assertion NP1404213.RAppPbBBST-2J_C8aaueTXrzoSp9jR0y24e9krOW2p1MY130_head.
- NP1404213.RAppPbBBST-2J_C8aaueTXrzoSp9jR0y24e9krOW2p1MY130_assertion description "[To determine if ovarian cancer patients would be suitable for MAGE-peptide vaccine-based immunotherapy, the frequency of expression of the MAGE-1-4 genes in ovarian tumours was assessed using reverse transcription polymerase chain reaction (RT-PCR) and product verification with digoxigenin-labelled oligonucleotide probes specific for each MAGE gene.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1404213.RAppPbBBST-2J_C8aaueTXrzoSp9jR0y24e9krOW2p1MY130_provenance.
- NP1404213.RAppPbBBST-2J_C8aaueTXrzoSp9jR0y24e9krOW2p1MY130_assertion evidence source_evidence_literature NP1404213.RAppPbBBST-2J_C8aaueTXrzoSp9jR0y24e9krOW2p1MY130_provenance.
- NP1404213.RAppPbBBST-2J_C8aaueTXrzoSp9jR0y24e9krOW2p1MY130_assertion SIO_000772 9743307 NP1404213.RAppPbBBST-2J_C8aaueTXrzoSp9jR0y24e9krOW2p1MY130_provenance.
- NP1404213.RAppPbBBST-2J_C8aaueTXrzoSp9jR0y24e9krOW2p1MY130_assertion wasDerivedFrom befree-2016 NP1404213.RAppPbBBST-2J_C8aaueTXrzoSp9jR0y24e9krOW2p1MY130_provenance.
- NP1404213.RAppPbBBST-2J_C8aaueTXrzoSp9jR0y24e9krOW2p1MY130_assertion wasGeneratedBy ECO_0000203 NP1404213.RAppPbBBST-2J_C8aaueTXrzoSp9jR0y24e9krOW2p1MY130_provenance.